At #ESMO26, @sonpavde discusses a phase 1/2 study of the PARP1-selective inhibitor EIK1003 with abiraterone in metastatic #ProstateCancer, its safety vs first-generation PARP inhibitors, and which patients may benefit

@myESMO #PCSM